Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial

The Lancet Gastroenterology and Hepatology

Volumn 1, Issue 1, 2016, Pages 25-35

  Asselah, Tarik ^a   Hézode, Christophe ^b   Qaqish, Roula B ^c   ElKhashab, Magdy ^d   Hassanein, Tarek ^e   Papatheodoridis, George ^f   Feld, Jordan J ^d   Moreno, Christophe ^g   Zeuzem, Stefan ^h   Ferenci, Peter ⁱ   Yu, Yao ^c   Redman, Rebecca ^c   Pilot Matias, Tami ^c   Mobashery, Niloufar ^c  

^a CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c ABBVIE INC   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e Southern California Liver Centers and Southern California Research Center   (United States)

^f UNIVERSITY OF ATHENS   (Greece)

^g ERASME HOSPITAL   (Belgium)

^h GOETHE UNIVERSITY   (Germany)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; VIRUS RNA; ABT-267; ABT-450; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND;

ADULT; ANEMIA; ARTICLE; ASTHENIA; CONTROLLED STUDY; DISEASE ASSESSMENT; DIZZINESS; DRUG SAFETY; FATIGUE; FEMALE; FIBRO TEST SCORE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEXT GENERATION SEQUENCING; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SUSTAINED VIROLOGICAL RESPONSE; VIROLOGY; ADOLESCENT; AGED; CHRONIC HEPATITIS C; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; FOLLOW UP; GENETICS; GENOTYPE; HEPACIVIRUS; MIDDLE AGED; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; RIBAVIRIN; RITONAVIR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84980728956     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(16)30001-2     Document Type: Article

References (32)

1. 1 Messina, JP, Humphreys, I, Flaxman, A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
2. 2 Wantuck, JM, Ahmed, A, Nguyen, MH, Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 39 (2014), 137–147.
3. 3 Gower, E, Estes, C, Blach, S, Razavi-Shearer, K, Razavi, H, Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61 (2014), S45–S57.
4. 4 Hajarizadeh, B, Grebely, J, Dore, GJ, Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 10 (2013), 553–562.
5. 5 Paez Jimenez, A, Mohamed, MK, Eldin, NS, et al. Injection drug use is a risk factor for HCV infection in urban Egypt. PLoS One, 4, 2009, e7193.
6. 6 Ray, SC, Arthur, RR, Carella, A, Bukh, J, Thomas, DL, Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 182 (2000), 698–707.
7. 7 Al Ashgar, HI, Khan, MQ, Al-Ahdal, M, et al. Hepatitis C genotype 4: genotypic diversity, epidemiological profile, and clinical relevance of subtypes in Saudi Arabia. Saudi J Gastroenterol 19 (2013), 28–33.
8. 8 Marcellin, P, Cheinquer, H, Curescu, M, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 56 (2012), 2039–2050.
9. 9 Asselah, T, Bourliere, M, Hepatitis C virus: current and evolving treatments for genotype 4. Gastroenterol Clin North Am 44 (2015), 859–870.
10. 10 Asselah, T, De Muynck, S, Broet, P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 56 (2012), 527–532.
11. 11 AASLD IDSA, IAS–USA. HCV Guidance: recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report-view (acccessed Dec 2, 2015).
12. 12 European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 63 (2015), 199–236.
13. 13 ZEPATIER (elbasvir and grazoprevir). Prescribing Information, 2016, Merck & Co, Inc, Whitehouse Station, NJ.
14. 14 Feld, JJ, Jacobson, IM, Hezode, C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373 (2015), 2599–2607.
15. 15 A 4-drug combination (Viekira Pak) for hepatitis C. Med Lett Drugs Ther 57 (2015), 15–17.
16. 16 Hezode, C, Asselah, T, Reddy, KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 385 (2015), 2502–2509.
17. 17 VIEKIRAX (ombitasvir paritaprevir/ritonavir). Summary of Product Characteristics, 2015, AbbVie Ltd, Maidenhead, UK.
18. 18 Koletzki, D, Dumont, S, Vermeiren, H, Fevery, B, De Smet, P, Stuyver, LJ, Development and evaluation of an automated hepatitis C virus NS5B sequence-based subtyping assay. Clin Chem Lab Med 48 (2010), 1095–1102.
19. 19 Ansaldi, F, Bruzzone, B, Salmaso, S, et al. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 76 (2005), 327–332.
20. 20 Doss, W, Shiha, G, Hassany, M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 63 (2015), 581–585.
21. 21 Ruane, PJ, Ain, D, Stryker, R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 62 (2015), 1040–1046.
22. 22 Lawitz, E, Gane, EJ, Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 369 (2013), 678–679.
23. 23 HARVONI (ledipasvir and sofosbuvir). Prescribing Information, 2015, Gilead Sciences, Foster City, CA.
24. 24 Abergel, A, Loustaud-Ratti, V, Metivier, S, et al. Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection. J Hepatol 62 (2015), S213–S234.
25. 25 Fontaine, H, Hezode, C, Zoulim, F, et al. Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the French observational cohort ANRS CO22 HEPATHER. J Hepatol, 62, 2015, S278.
26. 26 El Raziky, M, Gamil, M, Hammad, R, et al. Treatment of hepatitis C genotype 4 patients with simeprevir and sofosbuvir: preliminary results from a phase IIa, partially randomised, open-label trial conducted in Egypt (OSIRIS). Hepatology, 61(suppl 1), 2015, 784A.
27. 27 Asselah, T, Reesink, HW, Gerstoft, J, et al. High efficacy of grazoprevir and elbasvir with or without ribavirin in 103 treatment-naive and experienced patients with HCV genotype 4 infection: a pooled analysis. Hepatology, 62, 2015, 340A.
28. 28 O'Donnell, C, Burns, N, Dowrick, C, Lionis, C, MacFarlane, A, RESTORE team. Health-care access for migrants in Europe. Lancet, 382, 2013, 393.
29. 29 Di Lello, FA, Neukam, K, Parra-Sanchez, M, et al. Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves. J Med Virol 85 (2013), 1734–1740.
30. 30 Waked, I, Shiha, G, Qaqish, RB, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol, 2016 published online June 16. http://dx.doi.org/10.1016/S2468-1253(16)30002-4.
31. 31 Poordad, F, Hezode, C, Trinh, R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370 (2014), 1973–1982.
32. 32 Feld, JJ, Moreno, C, Trinh, R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol 64 (2016), 301–307.